Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Carboxymethylated β-glucan is a chemically modified, water-soluble derivative of β(1→3)(1→6) glucan, typically sourced from yeast (e.g., Saccharomyces species). This compound demonstrates antioxidant, immunomodulatory, anti-inflammatory, and wound-healing properties. As a derivative of β-glucan, it is more soluble and bioavailable, facilitating oral and topical applications. Carboxymethylated β-glucan has been studied for its ability to reduce oxidative stress (e.g., lowering malondialdehyde), promote immune responses, modulate macrophage activity, and accelerate wound healing. It is also investigated as a component of nanocarriers for antigen delivery and as a sprayable hydrogel for enhancing tissue regeneration and healing, particularly in diabetic models. Its mechanism involves modulation of the innate immune system and antioxidant pathways, though no unique molecular target has been specifically identified[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on carboxymethylated β-glucan.